Cargando…
COVID-19: the Risk to Athletes
PURPOSE OF REVIEW: The COVID-19 pandemic has had a profound impact on athletics, and the question of safely resuming competitive sports at all levels has been a source of significant debate. Concerns regarding myocarditis and the risk of arrhythmias and sudden death in athletes have prompted heighte...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519743/ https://www.ncbi.nlm.nih.gov/pubmed/34690485 http://dx.doi.org/10.1007/s11936-021-00941-2 |
_version_ | 1784584515181608960 |
---|---|
author | Goergen, Jack Bavishi, Aakash Eimer, Micah Zielinski, Allison R. |
author_facet | Goergen, Jack Bavishi, Aakash Eimer, Micah Zielinski, Allison R. |
author_sort | Goergen, Jack |
collection | PubMed |
description | PURPOSE OF REVIEW: The COVID-19 pandemic has had a profound impact on athletics, and the question of safely resuming competitive sports at all levels has been a source of significant debate. Concerns regarding myocarditis and the risk of arrhythmias and sudden death in athletes have prompted heightened attention to the role of cardiovascular screening. In this review, we aim to comprehensively outline the cardiovascular manifestations associated with COVID-19 infection, to discuss screening, diagnosis, and treatment strategies, and to evaluate the current literature on the risk to athletes and recommendations regarding return-to-play. RECENT FINDINGS: COVID-19 is known to cause myocarditis, with presentations ranging from subclinical current or prior infection detected on cardiac MRI imaging, to fulminant heart failure and shock. While initial data early in the pandemic suggested that the risk of myocarditis could be significant even in patients with nonsevere COVID-19 infection, recent studies suggest a very low prevalence of clinically significant disease in young athletes. SUMMARY: While COVID-19 can have significant cardiovascular manifestations, recent data demonstrate that a screening approach guided by severity of COVID-19 infection and cardiovascular symptoms allows the majority of athletes to safely return to play in a timely manner. We must continue to tailor our approach to screening athletes as knowledge grows, and further research on the longitudinal cardiovascular effects of COVID-19 is needed. |
format | Online Article Text |
id | pubmed-8519743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-85197432021-10-18 COVID-19: the Risk to Athletes Goergen, Jack Bavishi, Aakash Eimer, Micah Zielinski, Allison R. Curr Treat Options Cardiovasc Med Sports Cardiology (M Wasfy, Section Editor) PURPOSE OF REVIEW: The COVID-19 pandemic has had a profound impact on athletics, and the question of safely resuming competitive sports at all levels has been a source of significant debate. Concerns regarding myocarditis and the risk of arrhythmias and sudden death in athletes have prompted heightened attention to the role of cardiovascular screening. In this review, we aim to comprehensively outline the cardiovascular manifestations associated with COVID-19 infection, to discuss screening, diagnosis, and treatment strategies, and to evaluate the current literature on the risk to athletes and recommendations regarding return-to-play. RECENT FINDINGS: COVID-19 is known to cause myocarditis, with presentations ranging from subclinical current or prior infection detected on cardiac MRI imaging, to fulminant heart failure and shock. While initial data early in the pandemic suggested that the risk of myocarditis could be significant even in patients with nonsevere COVID-19 infection, recent studies suggest a very low prevalence of clinically significant disease in young athletes. SUMMARY: While COVID-19 can have significant cardiovascular manifestations, recent data demonstrate that a screening approach guided by severity of COVID-19 infection and cardiovascular symptoms allows the majority of athletes to safely return to play in a timely manner. We must continue to tailor our approach to screening athletes as knowledge grows, and further research on the longitudinal cardiovascular effects of COVID-19 is needed. Springer US 2021-10-15 2021 /pmc/articles/PMC8519743/ /pubmed/34690485 http://dx.doi.org/10.1007/s11936-021-00941-2 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Sports Cardiology (M Wasfy, Section Editor) Goergen, Jack Bavishi, Aakash Eimer, Micah Zielinski, Allison R. COVID-19: the Risk to Athletes |
title | COVID-19: the Risk to Athletes |
title_full | COVID-19: the Risk to Athletes |
title_fullStr | COVID-19: the Risk to Athletes |
title_full_unstemmed | COVID-19: the Risk to Athletes |
title_short | COVID-19: the Risk to Athletes |
title_sort | covid-19: the risk to athletes |
topic | Sports Cardiology (M Wasfy, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519743/ https://www.ncbi.nlm.nih.gov/pubmed/34690485 http://dx.doi.org/10.1007/s11936-021-00941-2 |
work_keys_str_mv | AT goergenjack covid19therisktoathletes AT bavishiaakash covid19therisktoathletes AT eimermicah covid19therisktoathletes AT zielinskiallisonr covid19therisktoathletes |